Blockade of Persistent Sodium Currents Contributes to the Riluzole-Induced Inhibition of Spontaneous Activity and Oscillations in Injured DRG Neurons by Xie, Rou-Gang et al.
Blockade of Persistent Sodium Currents Contributes to
the Riluzole-Induced Inhibition of Spontaneous Activity
and Oscillations in Injured DRG Neurons
Rou-Gang Xie
1., Da-Wei Zheng
1., Jun-Ling Xing
1., Xu-Jie Zhang
1,2., Ying Song
1,4, Ya-Bin Xie
1, Fang
Kuang
1, Hui Dong
3, Si-Wei You
1, Hui Xu
1*, San-Jue Hu
1*
1Institute of Neuroscience, Xi Jing Hospital, The Fourth Military Medical University, Xi’an, People’s Republic of China, 2School of Stomatology, Xi Jing Hospital, The Fourth
Military Medical University, Xi’an, People’s Republic of China, 3Department of Anaesthiology, Xi Jing Hospital, The Fourth Military Medical University, Xi’an, People’s
Republic of China, 4Jiangsu Province Key Laboratory of Anesthesiology, Xuzhou Medical College, Xuzhou, People’s Republic of China
Abstract
In addition to a fast activating and immediately inactivating inward sodium current, many types of excitable cells possess a
noninactivating or slowly inactivating component: the persistent sodium current (INaP). The INaP is found in normal primary
sensory neurons where it is mediated by tetrodotoxin-sensitive sodium channels. The dorsal root ganglion (DRG) is the
gateway for ectopic impulses that originate in pathological pain signals from the periphery. However, the role of INaP in DRG
neurons remains unclear, particularly in neuropathic pain states. Using in vivo recordings from single medium- and large-
diameter fibers isolated from the compressed DRG in Sprague-Dawley rats, we show that local application of riluzole, which
blocks the INaP, also inhibits the spontaneous activity of A-type DRG neurons in a dose-dependent manner. Significantly,
riluzole also abolished subthreshold membrane potential oscillations (SMPOs), although DRG neurons still responded to
intracellular current injection with a single full-sized spike. In addition, the INaP was enhanced in medium- and large-sized
neurons of the compressed DRG, while bath-applied riluzole significantly inhibited the INaP without affecting the transient
sodium current (INaT). Taken together, these results demonstrate for the first time that the INaP blocker riluzole selectively
inhibits INaP and thereby blocks SMPOs and the ectopic spontaneous activity of injured A-type DRG neurons. This suggests
that the INaP of DRG neurons is a potential target for treating neuropathic pain at the peripheral level.
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Introduction
Voltage-dependent sodium channels are responsible for the
generation and conduction of action potentials in the membranes
of excitable cells. In addition to a fast activating and immediately
inactivating sodium current, the inward current of many types of
excitable cells also has a non-inactivating or slowly inactivating
component: the persistent sodium current (INaP). The INaP is
present in neurons throughout the central nervous system,
including those of the hippocampus, neocortex and cerebellum
[1]; it has also been found in thalamic neurons [1,2], mesence-
phalic trigeminal sensory neurons [3], and hypoglossal motoneu-
rons [4]. When present, INaP lowers the actviation threshold of
most neurons by about 10 mV, and is blocked by a low level of
tretrodotoxin (100 nM) [1,5,6]. Under physiological conditions,
INaP is critical to neuronal excitability, the modulation of near-
threshold membrane potentials, the amplification of synaptic
currents, and the facilitation of repetitive firing [7,8,9,10]. There is
evidence from a genetic model of amyotrophic lateral sclerosis and
spinal cord injury that an increased persistent sodium current
determines the hyperexcitability of central cortical neurons
[11,12]. It also has been reported that INaP participates in epileptic
firing in the central nervous system [5]. Among such cells as
mesencephalic trigeminal sensory neurons and hippocampal
neurons, INaP is considered to be one of the threshold currents
modulating neuronal excitability under both physiological and
pathological conditions.
Recently, a number of reports have focused on the effects of
riluzole on INaP in central neurons [13,14,15,16,17], and have
proposed riluzole as a relatively specific persistent sodium channel
blocker [18,19]. Riluzole has been used clinically in the treatment
of several neurological disorders, including amyotrophic lateral
sclerosis [20] and epilepsy. However, the mechanisms underlying
these clinical applications are far from clear.
The dorsal root ganglion (DRG) is the gateway for ectopic
impulses originating in pathological pain signals from the
periphery. The INaP has been found in normal primary sensory
neurons where it is mediated by tetrodotoxin-sensitive sodium
channels [21]. However, the role of INaP in DRG neurons is
uncertain, particularly in neuropathic pain states. Our recent work
has shown that in compressed DRG neurons, INaP is blocked by
gabapentin and low doses of lidocaine, and that these analgesic
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18681drugs suppress the submembrane potential oscillations of injured
DRG neurons [22,23].
In the present study we demonstrate that behavioral changes in
rats undergoing a chronic compression of the dorsal root ganglion
(CCD) [24,25] are concurrent with a significant enhancement of
INaP, along with its associated subthreshold membrane potential
oscillations (SMPOs) and ectopic spotaneous activity (SA), in the
correspondingly injured A-type DRG neurons. Local application
of riluzole clearly inhibits INaP while suppressing SMPOs and SA,
indicating a potential role for the INaP of injured DRG neurons in
neuropathic pain states.
Materials and Methods
1. CCD animal model
Experiments were conducted on adult Sprague–Dawley rats
(200–250 g) of both sexes. The animals were purchased from the
Animal Center of the Fourth Military Medical University
(FMMU) and were housed and handled according to the
guidelines of the institutional and national Committees of Animal
Use and Protection.
The animal model used in this study was established in our
department as described previously [24,25]. In the present study, a
stainless steel L-shaped rod (4 mm in length and 0.66 mm in
diameter) was implanted in the intervertebral forman at L5 to
chronically compress the DRG.
2. Behavioral testing
Mechanical paw withdrawal threshold. Paw withdrawal
thresholds to mechanical stimulation were assessed using von Frey
filaments (Stoelting Co, USA). Each animal was placed on a metal
mesh floor in a plastic cage (20625615 cm). To test the tactile
threshold required to evoke withdrawal of the stimulated paw, von
Frey filaments (2–15.0 g) were applied perpendicularly in
ascending order to the plantar part of the hind paw [26].
Withdrawal, flicking, or licking of the hind paw were all
considered positive responses. Each filament was applied five
times, with the overall response assessed as positive if three or
more positive responses of the hind paw were obtained. The paw
withdrawal threshold was determined by the lowest strength of
stimulation. To avoid tissue damage, the cut off threshold was
assigned at 15.0 g [27].
3. Electrophysiological recordings
3.1 Extracellular recording of DRG single fiber
activities. Unit activities of single DRG A-fibers were
recorded 3–8 days after the CCD surgery. Under sodium
pentobabital anesthesia (40 mg/kg, i.p.), laminectomies were
performed at the L1–L2 and L4–L5 levels separately, and two
small pools were formed above the exposure regions. In the L4–L5
pool the stainless steel rod was removed. The spinal nerve was
transected 7–10 mm distal to the DRG so that the discharge
activities of the dorsal root fibers would originate primarily from
the DRG region and not from peripheral sources. During
recording the L4–L5 pool was filled with warm Krebs solution
(35–37uC) containing (in mM): NaCl 150, KCl 5, CaCl2 2, MgCl2
1, D-glucose 10 and HEPES 10, with the pH adjusted to 7.4.
The L1–L2 pool was filled with warm paraffin oil (35–37uC).
Under a microscope, a microfilament (20–50 mm in diameter) and
presumably including up to a few nerve fibers was isolated from
the dorsal root and cut off. The proximal end was placed on a fine
platinum electrode (29 mm in diameter) for electrophysiological
recording of DRG single fiber activities. The firing patterns of a
single fiber were displayed on a memory oscilloscope (VC-11,
Japan) and recorded via an A/D board to a computer hard drive
and stored for offline analysis. Unit activities with identical wave
forms were selected as single fiber activities [24,28].
Riluzole (Sigma, USA) was dissolved in dimethyl sulfoxide
(DMSO) as a stock solution and kept frozen; it was diluted in
ACSF before the experiments. Unit discharges were recorded in
the presence and absence of riluzole or vehicle for at least another
3 min. The percentage changes in discharge rate were calculated
as: (maximal discharge rate - baseline rate)/baseline rate6100%.
The changes in single fiber firing rates were considered significant
if the differences were 15% or greater [28].
3.2 Intracellular recording of SMPOs in DRG
neurons. In order to examine the effects of riluzole on these
oscillations, DRG neurons from CCD animals were intracellularly
recorded in vivo using sharp electrodes. The compressed DRG was
exposed under sodium pentobabital anesthesia (40 mg/kg, i.p.). A
small pool was formed surrounding the CCD ganglion and filled
with warm paraffin oil, as described above. Recording
microelectrodes were pulled from borosilicate glass tubes using a
microelectrode puller (P97, Sutter Instruments, USA). After being
filled with 3 M potassium acetate the microelectrodes had a final
resistance of 40–60 MV. DRG neurons were impaled under visual
control by advancing the microelectrode at 4–8 mm steps, with
application of a small capacitance buzz when necessary.
The conduction velocity was measured by delivering a brief
electrical pulse to the sciatic nerve through a stimulus isolator.
DRG neurons were categorized by their conduction velocities
[29]. Only A-type neurons with conduction velocities of 15.0–
35.1 m/s having stable resting membrane potentials below
250 mV and/or spontaneous activity were selected for further
investigation. Recordings were terminated if the resting membrane
potential dropped more than 10% below control values. Riluzole
(80 mM) was locally applied after control recordings.
3.3 Whole-cell patch recording of sodium currents in
DRG neurons. Three to eight days after the CCD surgery, the
animals that showed the positive behavioral responses described
above were selected for further electrophysioloical recordings.
After these animals were anesthetized with sodium pentobarbital
(50 mg/kg, i.p.), the compressed L5 DRGs were carefully removed
from the vertebral column and placed in cold oxygenated ACSF.
The ACSF contained (in mM): NaCl 125, KCl 2.5, NaH2PO4 1.2,
MgCl2 1.0, CaCl2 2.0, NaHCO3 25, and D-glucose 10. The
connective tissue was gently removed under a microscope and the
ganglia were digested with a mixture of 0.4 mg/ml trypsin (Sigma)
and 1.0 mg/ml A-type collagenase (Sigma) for 40 min at 37uC
while agitated by gentle bubbling with 95% O2 and 5% CO2.
Finally, the ganglion was transferred into a holding chamber
containing normal ACSF bubbled with 95% O2 and 5% CO2 at
26uC [23].
Recording electrodes had resistances of 4–8 MV after being
filled with an internal solution. To measure membrane potentials
and the effects of riluzole on the SMPOs of A-type DRG neurons,
the internal solution contained (in mM): KCl 140, MgCl2 2,
HEPES 10, Mg-ATP 2, with the pH adjusted to 7.4. To examine
the effects of riluzole on sodium currents in A-type DRG neurons,
recording electrodes were filled with an internal solution
containing (in mM): CsCl 110, NaCl 5, MgCl2 3, CaCl2 1,
EGTA 3 and HEPES 40, adjusted with Tris buffer to pH 7.4. The
bath solution consisted of (in mM): NaCl 100, TEA-Cl
(tetraethylammonium chloride) 40, KCl 3, MgCl2 1, CaCl2 1,
D-glucose 10, HEPES 10, BaCl2 1, CsCl 1, 4-AP (4-aminopyr-
idine) 2 and CdCl2 0.1, with the pH adjusted to 7.4 [30].
The ganglion was kept in the holding chamber for at least 1 hr
before being transferred to the recording chamber. During
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warm (32uC) ACSF saturated with 95% O2 and 5% CO2.
Individual neurons were visualized with a 406 water-immersion
objective under a microscope (BX51WI; Olympus) equipped with
infrared differential interference contrast optics. Whole-cell
current and voltage recordings were carried out using a Multi-
clamp 700B amplifier (Molecular Devices, USA). The signals were
digitized at 10 kHz by a 1320 A/D board (Molecular Devices,
USA) and stored in a computer hard drive for offline analysis. P-
clamp 9 software (Molecular Devices, USA) was used for data
acquisition and analysis. Typically, a gigaohm seal was formed by
a small negative pressure, and whole-cell recording was established
by rupture of the cell membrane with further negative pressure or
a buzz signal, or a combination of both. Membrane potential was
held at 260 mV under voltage clamp. Neurons that showed
resting membrane potentials below 250 mV along with over-
shooting action potentials were selected for further study.
Recordings were terminated if the Ra increased or resting
membrane potential dropped by 20% or more from control levels.
Sodium current amplitude was transformed into conductance
using the Ohm’s law in the form: G=I/(V2ENa), where V is the
test potential and ENa is the Na
+ equilibrium potential calculated
using the Nernst equation. Conductance was normalized, plotted
against V and fitted with a Boltzmann function of the form: G/
Gmax=1/{1+exp[(V2V1/2)6k
21 ]}, where V1/2 is the half-
activation voltage and k is the slope factor.
4. Statistical analysis
All values were expressed as mean 6 SEM. Statistical
evaluations were performed using Statistical Product and Service
Solutions (SPSS) software (paired t-test, non-paired t-test, repeated
measure, and one-way AVOVA methods) with the significance
criterion set at P=0.05.
Results
1. Mechanical allodynia in CCD animals
During the behavioral test period which lasted for up to two
weeks, all animals appeared to be gaining weight, which suggests
that they were in good health. Animals were usually well groomed
and exhibited no self-inflicted wounds. No abnormal gait or
posture was observed in the control group. However, all tested rats
post-CCD surgery developed varying degrees of gait and postural
abnormality. They were often seen to lift the ipsilateral hindpaw
from the ground and then hold it in a protected position next to
the flank while standing or sitting. When the affected hindpaw was
touching the ground, the animals often reduced the weight placed
on it by leaning to the other side or by sitting on the opposite
haunch. These behaviors appeared as early as one day after the
CCD surgery, and all animals showed such behaviors within the
first two weeks, as reported earlier [24,25]. No control or test
animals exhibited any signs of autotomy or abnormal nail growth.
However, the CCD rats used for subsequent electrophysiological
recordings showed clear behavioral indications of allodynia, as
reported previously [24,25].
As shown in Figure 1A, the thresholds for paw withdrawal in
control animals were relatively stable (8.560.4 g, n=6), while the
values for the same tests on the contralateral side were slightly
decreased (Fig. 1B), but not to a statistically significant extent (non-
paired t-test, P.0.05). However, the thresholds for paw with-
drawal on the ipsilateral side of the CCD animals were clearly
reduced starting on the day after the CCD surgery (one-way
AVOVA method, P,0.05). The reductions became statistically
significant from day 5 on and remained low until the end of the
tests (4.060.8 g, n=4; non-paired t-test, P,0.05, Fig. 1A). These
behavioral responses of the CCD animals are characteristic of
mechanical allodynia. Similar results have been reported by our
group [24] and by others [25].
2. Inhibitory effects of INaP blocker riluzole on the
spontaneous activity of A-type fibers from compressed
DRG neurons
A total of 53 spontaneously discharging A-type single fibers of
the L5 DRG were recorded from 38 CCD ganglions in intact
animals. CCD fibers/neurons can be classified into two classes
based on the dynamic features of their spontaneous activities [28].
The periodic class is characterized by the interspike intervals that
appear repeatedly at regular intervals, and 21 of 53 fibers (39.6%)
fell into this category. Fibers in the non-periodic class have an
irregular pattern of interspike intervals, and 32 of 53 fibers (60.4%)
were included in this group.
Basal firing rates normally fluctuated from 0.6% to 14.2% of the
average control value (6.460.5%, n=53). Five minutes after local
application of the INaP blocker riluzole (100 mM) to the DRG
region, rates of spontaneous activity were reduced in all cases
Figure 1. Mechanical allodynia in CCD rats. (A) Time course of changes in the withdrawl threshold of the ipsilateral hindpaw for control (n=6,
open circles) and CCD (n=4, closed circles) rats. The mechanical threshold for withdrawl of the ipsilateral hindpaw was significantly lower in the
chronically compressed rats (* P,0.05 or **P,0.01 compared with the average for the ipsilateral hindpaw of the control group). (B) Average
ipsilateral and contralateral paw withdrawl thresholds for the control and CCD groups on the postoperative 5 days.
doi:10.1371/journal.pone.0018681.g001
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reversibly abolished after the riluzole application. The results of
similar recordings can be summarized as showing that the
spontaneous activity of A-type CCD fibers is suppressed by
riluzole in a dose-dependent manner (n=6, Fig. 2B). Again, the
riluzole-mediated inhibition of the spontaneous activity in A-type
CCD fibers was shown to be reversible in most cases, as the
spontaneous activity resumed in 78.6% (22/28) of the fibers within
20 min after washout (Fig. 2A). In the presence of 0.1% DMSO,
the discharge rate of A-type fibers from compressed DRG neurons
was 19.962.9 Hz (n=4), which is not significantly different from
the discharge rate of A-type fibers in the absence of the vehicle
(paired t-test, P.0.05).
3. Inhibitory effects of riluzole on SMPOs in compressed
A-type DRG neurons
3.1 Inhibitory effects of riluzole on spontaneous SMPOs
at the resting membrane potential. The SMPOs observed in
DRG neurons of CCD animals can be considered a useful
electrophysiological indication of neuronal injury. To examine
whether riluzole affects SMPOs and would thereby block such
downstream effects, DRG neurons in CCD animals were recorded
in vivo using sharp electrodes. Upon penetration, most of these DRG
neurons were silent and had a relatively stable membrane potential
(261.360.9 mV, n=30), but some (7/63, 11.1%) displayed
sinusoidal SMPOs (78.263.4 Hz, n=12) and spontaneous activity
at the resting membrane potential. After a 5 min period of baseline
recording from 4 of such neurons, riluzole (80 mM) was locally
applied onto the DRG. It was found that the resting membrane
potential remained stable in all of these cells, but that the frequency
of the spontaneous activity gradually decreased and finally
disappeared in about 60 s. The SMPOs showed similar changes,
decreasing in amplitude and then disappearing. The inhibition of
riluzole on spontaneous activity and SMPOs was largely recovered
following washout in all the tested neurons (Fig. 3A).
3.2 Inhibitory effects of riluzole on the spontaneous
activity in vitro. Few if any DRG neurons recorded using
whole-cell patch-clamp methods displayed spontaneous activity
following the compression of the DRG. The effects of riluzole were
examined in these neurons by the bath application of the drug
(10 mM) to three DRG neurons in vitro, after which the
spontaneous activity slowed down and eventually was eliminated
(Fig. 3B).
3.3 Inhibitory effects of riluzole on SMPOs at different
levels of depolarization. Using whole-cell patch-clamp
methods, about a third of the recorded DRG cells (10/28,
35.7%) displayed high frequency sinusoidal SMPOs and repetitive
discharges during the injection of 800 ms depolarizing current
pulses. The effects of riluzole were examined in five of these
neurons by the bath application of the drug (10 mM). It was found
that the SMPOs were eliminated and that the repetitive firing
slowed down and eventually stopped 3 min after the drug
Figure 2. Effects of riluzole on the spontaneous activity of A-type neurons in the compressed DRG. (A) Time histogram showing that
local application of the INaP blocker riluzole reduces the basal firing rate of an A-type fiber in a dose-dependent manner (n=6; P,0.05). (B) Percent
inhibition of spontaneous activity in A-type fibers with respect to the concentration of locally-applied riluzole (mM; n=6; *P,0.05, **P,0.01,
***P,0.001). (C) Time histogram showing the suppression of spontaneous activity induced by riluzole (100 mM) in an A-type afferent fiber from a
compressed DRG. Expanded traces in right panel show firing patterns before (a) and during (b) the drug application.
doi:10.1371/journal.pone.0018681.g002
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PLoS ONE | www.plosone.org 4 April 2011 | Volume 6 | Issue 4 | e18681Figure 3. Effects of riluzole on the spontaneous activity and SMPOs of A-type neurons in the compressed DRG. (A) Intracellullar sharp
electrode recordings from an A-type DRG neuron in vivo, showing spontaneous activity and SMPOs under control conditions (a), after local
application of riluzole (80 mM; b,c), and during washout (d). The spikes have been truncated. Inserted segments (a–d, lower panel) are expansions of
the original traces at the times indicated and show details of the spikes and SMPOs. (B) Whole-cell patch recordings from an A-type DRG neuron in
vitro. Spontaneous activity (a) was significantly inhibited in the presence of riluzole (10 mM; b,c) and restored after washout (d). The spikes have been
truncated. Inserted segments (a–d, lower panel) are expansions of the original traces at the times indicated. (C) Whole-cell patch recordings from an
A-type DRG neuron in vitro. (a) The cell responded to depolarizing current pulses of 1.7 nA (upper panel) and 2.4 nA (lower panel) with repetitive
firing and SMPOs (insertion). (b) In the presence of 10 mM riluzole (upper panel), both the repetitive firing and SMPOs (insertion) induced by
depolarization were abolished; however, a single action potential was still evoked immediately after application of the current pulse.
doi:10.1371/journal.pone.0018681.g003
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abolished the evoked SMPOs and the repetitive firing, these DRG
neurons still responded to the same depolarizing current pulses
with a single action potential at the initial phase of the current
pulse, indicating that these cells are still capable of generating
action potentials in the presence of riluzole (Fig. 3C). In all the
neurons tested, the SMPOs and repetitive firing were largely
recovered after riluzole washout.
4. Increased INaP in injured A-type DRG neurons
Using whole-cell patch-clamp methods, 114 large- and medium-
sized neurons ($35 mm in diameter) were recorded in in vitro DRG
preparations taken from CCD animals. These neurons had a
stable resting potential of 255.760.9 mV (n=80), a membrane
resistance of 89.665.3 MV (n=80), and a membrane capacitance
of 92.463.3 pF (n=80).
In these experiments, the glass recording pipettes were filled
with a Cs
+-based internal solution, while K
+ and Ca
2+ channel
blockers were added to the bath. Under a holding potential of
260 mV, INaP was recorded in normal DRG neurons by applying
a 3 s depolarization ramp current from 280 to 0 mV [30]. The
inward sodium current was induced at potentials of 260 to
250 mV, reached a peak at 235 mV, returned to control levels at
220 mV (Fig. 4A), and was sensitive to a low dose of TTX
(100 nM, not shown). In injured A-type DRG neurons, the
average current density of INaP was also significantly increased
(CCD group: 2.860.3 pA/pF, control group: 1.660.3 pA/pF,
non-paired t-test, P,0.05; Fig. 4A–4C). The activation curves of
INaP in control and compressed DRG neurons were both fit with a
Boltzmann distribution equation; the differences were not
statistically significant (Fig. 4D).
5. Selective inhibitory effect of riluzole on INaP in injured
A-type DRG neurons
The average current peak of INaP in injured A-type DRG
neurons was 249.1648.3 pA or 248.4647.9 pA (n=4) in the
absence or presence of DMSO (0.1%), respectively, a difference
which is not statistically significant (paired t-test, P.0.05;
Fig. 4E&4F). Riluzole significantly inhibited the INaP of injured
A-type DRG neurons in a dose-dependent manner. At doses as
low as 2 mM, the drug clearly reduced the peak value of INaP by
,40% (n=5, non-paired t-test, P,0.05; Fig. 5A), and the IC50 for
riluzole inhibition of the INaP was 4.1 mM (n=5; Fig. 5B).
To determine the specificity of this riluzole-induced inhibition
in injured A-type DRG neurons, we next examined the effects of
the drug on the TTX-sensitive transient sodium current (INaT). In
whole-cell recordings performed under voltage-clamp, INaT was
evoked by depolarization voltage steps (Fig. 5C). Riluzole was then
bath-applied at 10, 200 and 500 mM, and the percent inhibition of
the INaT peak amplitude in each neuron was plotted against the
different voltage steps (Fig. 5D). The inhibition of INaT at 200 and
500 mM riluzole was 58.966.5% (n=4, paired t-test, P,0.05) and
82.061.7% (n=3, paired t-test, P,0.001), respectively.
Discussion
The primary finding of the present study is that a local
application of the INaP blocker riluzole to the DRG selectively
reduces the INaP and INaP-associated SMPOs of injured DRG
neurons in the CCD animal model of neuropathic pain. The INaP
is enhanced in medium- and large-sized DRG neurons of the
compressed DRG.. Our data shows for the first time that the INaP
and INaP-associated SMPOs of injured DRG neurons are
important to the spontaneous activity of primary afferents in
neuropathic pain states. Hence, the blockade of INaP in DRG
neurons may play an anti-nociceptive role at the primary afferent
level.
1. Spontaneous activity in neuropathic pain states
In our animal model, a chronic and steady compression is
ipsilaterally applied to the DRG in rats (CCD model), causing the
animals to show behaviors typical of mechanical allodynia
ipisilaterally [24]. Ectopic spontaneous activity plays an important
role in maintaining central sensitization and neuropathic pain.
Moreover, the level of ectopic discharge is generally well
correlated with the degree of pain behavior in neuropathic
animals [31]. Our in vivo experiment demonstrate that the
spontaneous activity of large diameter primary afferent fibers is
inhibited by the INaP blocker riluzole in a dose-dependent manner
and is completely abolished at a concentration of 500 mM. This
concentration of riluzole was slightly higher than that of the
riluzole used in our in vitro whole-cell patch-clamp experienments
of the present study, due to the rapid circulation of blood within
the DRG in vivo. These results indicate that the INaP blocker
riluzole inhibits the spontaneous activity of compressed type-A
DRG neurons, and hence reduces pathological pain signals
originating in the periphery.
2. SMPOs in A-type DRG neurons
Previous work has shown that low levels of TTX also suppress
SMPOs and abolish ectopic spontaneous activity in injured DRG
neurons [32,33,34], indicating that SMPOs of injured DRG
neurons are essential to the generation of abnormal spontaneous
activity and pain behaviors. The fact that peripheral receptors and
large parts of the axons were removed in our preparations suggests
that SMPOs must be generated in the soma or in proximal
segments of DRG cell axons. Hence, pathological hyperexcitabil-
ity may originate not only at receptors in the skin but also in the
somatic region of primary afferent neurons. Our recent work has
shown that analgesic drugs such as gabapentin and lidocaine have
inhibitory effects similar to those of riluzole on INaP [22,23]. The
results reported here further demonstrate that INaP plays an
important role in the generation of SMPOs that occur in injured
A-type DRG neurons after compression of the DRG. In the rat
trigeminal mesencephalic nuclei, INaP is responsible for the
enhancement of SMPOs and also participates in the generation
of bursting in central neurons [19]. Taken together, these studies
strongly suggest that injury and inflammation may cause large-
and medium-sized DRG neurons to increase a TTX-sensitive INaP
and its associated SMPOs. The latter may in turn facilitate the
generation of ectopic spontaneous activity, an important basis for
pathological pain signals in the periphery under neuropathic pain
states. Using sharp electrode recordings in vivo and whole-cell
patch-clamp recordings in vitro, we observed sine wave-like SMPOs
in DRG neurons. Moreover, although repetitive firing and
SMPOs were abolished by riluzole, DRG neurons still responded
to intracellular current injection with a single full-sized spike,
demonstrating that they are still capable of firing action potentials
under riluzole.
3. INaP in A-type DRG neurons
The vast majority of pain studies at the peripheral level have
focused on small DRG neurons (,25 mm in diameter) and their
fibers. However, in cases of allodynia the non-nociceptive stimuli
associated with these cells become nociceptive, and almost any
type of stimulus may cause pain. It is a reasonable hypothesis that
medium- and large-sized primary afferent fibers and their DRG
neurons are responsible for allodynia [35,36]. The present study
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further characterize allodynia’s cellular mechanisms.
INaP is a TTX-sensitive current that is activated in the
subthreshold voltage range and is slowly inactivating. Such
dynamics enable neurons to amplify their responses to synaptic
inputs, thereby driving them to spiking or repetitive firing [9,11].
To measure INaP directly, we injected ramp current into the
recorded cells while isolating the INaP by adding the non-selective
K
+ channel blocker cesium to the internal solution and the non-
selective Ca
2+ channel blocker cadmium to the bath [30]. Our
Figure 4. Enhanced INaP in A-type neurons of the compressed DRG. (A) Traces of INaP in A-type neurons from control (normal; grey line) and
compressed (CCD, solid line) DRGs (bottom) as induced by increasing applied voltage (top). (B) Bar graph showing that the average peak INaP is
significantly greater in neurons recorded from compressed DRGs (CCD; n=31) compared to the average peak value from control group recordings
(normal; n=26; *P,0.05). (C) Bar graph showing that average peak INaP current density is significantly greater in compressed DRG neurons (n=31)
compared to the average peak value from control group recordings (n=26; *P,0.05). (D) Steady state activation curves for INaP conductance with
respect to voltage in control and compressed DRG neurons as fit with a Boltzmann distribution equation. The differences are not statistically
significant. (E) Traces of INaP in a compressed DRG neuron in the absence (control, solid line) and presence (DMSO, grey line) of 0.1% DMSO (bottom)
as induced by increasing applied voltage (top). (F) Bar graph showing that average peak INaP in compressed DRG neurons (n=7) in the presence of
0.1% DMSO is not significantly different from the average peak INaP in the absence of DMSO (control, filled; n=7; P.0.05).
doi:10.1371/journal.pone.0018681.g004
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neurons and is blocked by the presence of a low concentration of
TTX (100 nM). Moreover, after induction of the ganglion
compression characteristic of the CCD model, INaP was signifi-
cantly increased in A-type DRG neurons. INaP activation curves for
compressed DRG neurons were not significantly different from
those of the control group. These results suggest that increased INaP
contributes to the hyperexcitability of injured A-type DRG
neurons.
There is evidence that under experimental pain conditions, at
least two types of Na
+ channels, Nav1.7 and Nav1.8, are
upregulated and downregulated concurrently with corresponding
effects on TTX-sensitive and TTX-insensitive currents [37]. The
sodium channel Nav1.7 is expressed predominantly in DRG and
sympathetic ganglion neurons [38,39,40,41], specifically in most
functionally-identified DRG nociceptive or small neurons [42].
This channel has been proposed as a molecular gatekeeper of pain
detection at peripheral nociceptors [43]. Nav1.7 is slowly
inactivated with dynamics similar to those of INaP [44]. The
expression of Nav1.7 in large- and medium-sized DRG cells, in
addition to its upregulation concurrent with changes in INaP, have
been observed in a model of diabetic neuropathy [45]. There is
also evidence that increased INaP determines cortical hyperexcit-
ability in a genetic model of amyotrophic lateral sclerosis [11].
4. Potential anti-nociceptive effects of INaP blocker
riluzole
Animal studies have shown that riluzole reduces the develop-
ment of mechanical and cold hyperactivities in a neuropathic pain
model through its pronounced suppression of glutamate and
aspartate levels in the spinal dorsal horn [46]. Riluzole also
attenuates formalin-induced flinching behaviors that follow from
its blocking effects on sodium channels, although a specific site of
this action has not been demonstrated [47]. In the rat, local
injection of riluzole into the ventral posterolateral thalamic nuclei
was found to reduce carrageenan-induced mechanical hyperalge-
Figure 5. Effects of riluzole on INaP and INaT in A-type neurons of the compressed DRG. (A) Traces of INaP (bottom) induced by increasing
applied voltage (top) in a compressed DRG neuron in the absence (control) and presence of riluzole (2, 10, 50 mM). (B) Dose-inhibition curve showing
effect of locally applied riluzole on INaP in compressed DRG neurons (n=5; IC50=4.3 mM). (C) INaT traces in a DRG neuron evoked by applied
depolarization (220 mV) under control conditions and in the presence of riluzole (10, 200, 500 mM). (D) Bar graph showing that average peak INaT
current density (pA/pF) in the presence of riluzole (10, 200, 500 mM) is significantly decreased in neurons recorded from compressed DRGs (*P,0.05,
**P,0.01).
doi:10.1371/journal.pone.0018681.g005
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was reported to induce anti-nociceptive effects along with a
general anesthetic state, probably by blocking glutamatergic
neurotransmission [49]. However, clinical research has shown
that oral administration of riluzole does not affect thermal and
mechanical hyperalgesia in patients with inflammatory pain [50]
or alleviate allodynia and mechanical hyperalgesia in neuropathic
pain patients [51].
These controversial effects of riluzole in clinical application and
animal research call for simplified model systems to explore its
basic mechanisms at cellular and molecular levels. To avoid the
complexity of riluzole’s effects on the CNS, we have systematically
investigated its effects on DRG neurons as representing the first
stage of the peripheral pain sensory system. We have shown that
riluzole selectively inhibits the INaP of injured A-type DRG
neurons, thereby suppressing their SMPOs and ectopic spotaneous
activity. Those results suggest that the INaP of DRG neurons can be
a potential target for analgesia at the peripheral level.
Our results indicating that riluzole may excert an anti-allodynia
effect in the DRG after nerve injury are also consistent with
reports that riluzole decreases the development of mechanical
allodynia in a rat model of neuropathic pain [46] and that the drug
attenuates nociceptive responses in a formalin-induced inflamma-
tory model [47]. Clinically, however, riluzole does not affect
thermal hyperalgesia in the inflammatory pain induced by heat
stimuli [50]. These results strongly suggest that riluzole selectively
reduces mechanical allodynia under neuropathic pain states, but is
not as effective in treating other types of pain that are conveyed via
thin afferent fibers. Compared with the anti-convulsant agents
gabapentin and lamotrigine, lower doses of riluzole were more
effective in relieving mechanical hypersensitivity. The effects of the
drug were also long-lasting, extending up to 12 days after
systematic administration [46]. Apparently, riluzole is much more
efficient than these other agents in reducing mechanical
hypersensitivity under conditions of neuropathic pain. The
discrepancy of its clinical ineffectiveness may be due to the use
of insufficient doses of the drug at local sites. Our recent work
showing that INaP is suppressed by gabapentin and low doses of
lidocaine in compressed DRG neurons [22,23], as well as the
inhibitory effects of riluzole in the same CCG model shown here,
indicate that the INaP of injured DRG neurons remains a potential
target for analgesia at the peripheral level.
From a clinical point of view, most pain symptoms in peripheral
neuropathy are of peripheral origin [52]. The gateway function of
the DRG suggests that the INaP of DRG neurons could be a
potential target in treating patients with peripheral pain
symptoms. Our results demonstrate that local application of INaP
blocker riluzole within the DRG could be specific and effective as
a peripherally-acting analgesic agent that does not penetrate the
blood-brain barrier and is therefore free of central nervous system
side effects [53].
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